Hims & Hers Health, Inc. (NYSE:HIMS) is one of the 10 Stocks Leave Wall Street Stunned.
Hims & Hers extended its rally for the second day on Friday, adding 6.76 percent to close at $49.41 apiece after its chief executive’s reaffirmation that the company will continue to offer cheaper compounded versions of GLP-1 weight-loss drugs, following its terminated partnership with Novo Nordisk.
According to Hims & Hers Health, Inc. (NYSE:HIMS) CEO Andrew Dudum, he was upset that Novo was feeling the pressure and was not comfortable.
A nurse in a telehealth platform talking with a patient on video call for consultation.
“But ultimately, I think us holding strong to fighting on behalf of customers is just who we are. There’s just no way in hell we’re going to cave on that, no matter who the pharma company is or what the partnership looks like,” he noted.
Novo Nordisk terminated its partnership with Hims & Hers Health, Inc. (NYSE:HIMS), alleging the latter of failing to adhere to the law, which prohibits mass sales of compounded drugs under the false guise of “personalization.”
Novo Nordisk also claimed that Hims & Hers Health, Inc. (NYSE:HIMS) was disseminating deceptive marketing that put patient safety at risk.
While we acknowledge the potential of HIMS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.
Disclosure: None. This article is originally published at Insider Monkey.
